Amsterdam Immunogenicity & Tolerance Seminar November 4-5, 2021

On July 21, 2021 EpiVax reported that new dates for this year’s Amsterdam Immunogenicity & Tolerance Seminar (Press release, EpiVax, JUL 21, 2021, View Source [SID1234590457])!

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The seminar is now a two-day, afternoon-only format. This arrangement leaves mornings free for attendees to network, collaborate in small groups, and enjoy the beautiful city of Amsterdam.

All events will take place at the Hilton Apollolaan. Apollolaan 138, 1077 BG, Amsterdam, Netherlands

Day 1, Thursday, November 4th
12:00 PM- 6 PM CET (Central European Time)

Lunch will be provided from 12-1 PM

A cocktail reception will be held at immediately following completion of Day 1 talks, from 6 – 8 PM

Day 2, Friday November 5th
1 PM – 5 PM CET (Central European Time)

Lunch will provided from 12-1 PM

The seminar will focus on translational research in the fields of immunogenicity and tolerance, with case studies touching on vaccines and biologics.

Interested in attending this free event? Register here!

We are so excited to return to Amsterdam and meet safely and responsibly with our colleagues for this in-person event. Please note that we will be monitoring the COVID-19 pandemic and travel restrictions, and we will communicate any changes in advance if the events cannot safely take place.

Special Guest Speakers will include:

Annie De Groot, MD
Research Professor, Center for Vaccines and Immunology, University of Georgia
CEO/CSO, EpiVax, Inc.

Amy Rosenberg, MD
Senior Director of Immunology and Protein Therapeutics, EpiVax, Inc.